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Visceral leishmaniasis (VL) caused by the protozoan parasite Leishmania infantum, is one of the most
important zoonotic diseases affecting dogs and humans in the Mediterranean area. The presence of
infected dogs as the main reservoir host of L. infantum is regarded as the most signiﬁcant risk for po-
tential human infection. We have studied the susceptibility proﬁle to antimony and other anti-
leishmania drugs (amphotericin B, miltefosine, paromomycin) in Leishmania infantum isolates extrac-
ted from a dog before and after two therapeutic interventions with meglumine antimoniate (subcu-
taneous Glucantime®, 100 mg/kg/day for 28 days). After the therapeutic intervention, these parasites
were signiﬁcantly less susceptible to antimony than pretreatment isolate, presenting a resistance index
of 6-fold to SbIII for promastigotes and >3-fold to SbIII and 3-fold to SbV for intracellular amastigotes. The
susceptibility proﬁle of this resistant L. infantum line is related to a decreased antimony uptake due to
lower aquaglyceroporin-1 expression levels. Additionally, other mechanisms including an increase in
thiols and overexpression of enzymes involved in thiol metabolism, such as ornithine decarboxylase,
trypanothione reductase, mitochondrial tryparedoxin and mitochondrial tryparedoxin peroxidase, could
contribute to the resistance as antimony detoxiﬁcation mechanisms. A major contribution of this study in
a canine L. infantum isolate is to ﬁnd an antimony-resistant mechanism similar to that previously
described in other human clinical isolates.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Leishmaniasis caused by the intracellular protozoan Leishmania
is the second most important parasitic disease after Malaria,
affecting humans and animals in wide areas of the Americas, Asia,
Africa and Europe. Domestic dogs are considered the main reser-
voir of Leishmania infantum, and a risk factor for anthroponotic
human visceral infection. Canine leishmaniasis (CanL) is endemic
and affects millions of dogs in Asia, Europe, North Africa and South
America, and is currently an emergent disease in North America. It
has been estimated that at least 2.5 million dogs are infected inare equal senior authors.
Ltd on behalf of Australian Society fsouthwestern Europe (Moreno and Alvar, 2002; Athanasiou et al.,
2012). The infection is spreading to non-endemic areas and cases
of CanL are reported with increasing frequency in Northern Euro-
pean countries and in the United Kingdom, even in dogs that have
never visited endemic zones (Shaw et al., 2009). The introduction
and spread of the disease to regions where infections had not
previously been observed may create new epidemiological sce-
narios, further complicating the zoonotic potential and control of
the disease.
In the absence of effective human and canine vaccines, the only
feasible way to treat and control leishmaniasis is through the use of
affordable chemotherapy. Meglumine antimoniate is one of the
most common drugs used in Europe to treat CanL (Solano-Gallego
et al., 2011). The combination of meglumine antimoniate with
allopurinol is considered to be the most effective therapy and
constitutes the ﬁrst line protocol against CanL (Miro et al., 2008).or Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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although it is extremely difﬁcult to achieve a parasitological cure in
dogs. For this reason, the majority of short-term therapeutic in-
terventions are usually followed by a relapse within 1 year of dis-
continuing treatment (Baneth and Shaw, 2002; Ikeda-Garcia et al.,
2007; Manna et al., 2008). As infected dogs never achieve parasi-
tological cure and are frequently treated several times with the
same compounds, selection and transmission of antimony-
resistant parasites could appear (Campino and Maia, 2012; Sereno
et al., 2012).
Therapeutic failure and relapse in leishmaniasis is known to
have a multifactorial origin, involving features related to the host
(immunity, genetic and nutritional factors, among others), the drug
(quality, pharmacokinetics) and the parasite (drug resistance,
increased infectivity, coinfection with other pathogens)
(Vanaerschot et al., 2014). While the occurrence of Leishmania
resistance to pentavalent antimonials is well known in human
medicine (Croft et al., 2006; Vanaerschot et al., 2013), only limited
information is available for dogs. L. infantum isolates taken from
dogs which had received several treatment courses have demon-
strated contradictory results, with no differences in susceptibility in
isolates from treated and untreated dogs (Carrio and Portús, 2002),
or a decreased susceptibility to antimony after several therapeutic
interventions (Gramiccia et al., 1992).
In the present study we investigate if a L. infantum isolate from a
dog with CanL relapse after a therapeutic intervention has devel-
oped drug resistance as a factor responsible of therapeutic failure,
and the mechanism of resistance developed. The singularity of this
study was based on the use of Leishmania isolates at the time of
diagnosis and after therapeutic interventions, facilitating the
comparative studies. It is important to detect resistant parasites in
dogs with therapeutic failure in order to avoid and reduce the
emergence and spread of resistant parasites throughout the canine
populations; a factor that requires special considerationwhen dogs
are treated with the same anti-leishmania drugs that are available
for human visceral leishmaniasis.
2. Materials and methods
2.1. Chemicals
Trivalent antimony (SbIII), amphotericin B (AmB), paromomycin,
Triton X-100, paraformaldehyde, 40,6-diamidino-2-phenylindole
dilactate (DAPI), n-dodecyl-b-D-maltoside (DDM), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
and phorbol 12-myristate 13-acetate (PMA) were obtained from
Sigma-Aldrich (St. Louis, USA). Miltefosine was purchased from
Æterna Zentaris (Frankfurt, Germany). Glucantime®was purchased
from Sanoﬁ-Aventis (Paris, France). L-glutamine and penicillin/
streptomycin were obtained from Gibco. All chemicals were of the
highest quality available.
2.2. Clinical case, parasite isolation and culture
A ﬁve-years-old male boxer dog was positively diagnosed for
leishmaniasis through detection of anti-leishmania speciﬁc anti-
bodies by indirect immunoﬂuorescence (IgG titer  1280) and by
detection of L. infantum parasites with qPCR (1.06 parasites/mL)
using speciﬁc primers for kDNA as described (Corpas-Lopez et al.,
2015). The animal had many clinical signs compatible with CanL,
including onychogryphosis, adenopathy, skin lesions and uveitis,
among others. The clinical status was quantiﬁed by determining a
Clinical Score (CS). Brieﬂy, each symptom was assigned a value
according to the severity of it (0¼ absence; 1¼mild; 2¼moderate;
3 ¼ severe) and the CS was the sum of the values for everysymptom. The initial clinical scores (CS ¼ 18) rises after the ﬁrst
treatment series (CS ¼ 24) and declined to the initial CS value after
the second one (CS ¼ 18). In the follow-up period without drug
pressure, the dog showed a higher CS value (CS ¼ 20), due to the
aggravation of eye symptoms (uveitis, keratitis) besides increased
creatinine.
After the trial, the dog was returned to its owner with full in-
formation on its clinical and parasitological state, who decided to
treat the animal with other drugs.
The dog was housed in the facilities of an animal shelter, with
access to water and food ad libitum. It was ﬁtted with a Scalibor®
deltamethrin collar at the time of the assay. The building where the
dog was housed was protected with adequate mosquito nets to
prevent sandﬂies from entering. This building was also sprayed
with insecticide (Fenitrothion) on a monthly basis.
Animal experiments were approved by the Ethics Committee for
Animal Experimentation of the University of Granada (Protocol:
450-26113) and all procedures were carried out according to the
international guidelines and the European Union Directive (86/609/
EEC). The dog was treated with meglumine antimoniate (Glu-
cantime®) at 100 mg/kg/day administered subcutaneously for two
28-day periods, separated by a 30-day interval.
The parasites were isolated from bone marrow and ganglion
aspirates in Evans’ Modiﬁed Tobie’s Medium (EMTM). After their
isolation, parasites were cultured at 28 C in RPMI-1640 medium
supplementedwith 10% heat-inactivated fetal bovine serum (hiFBS,
Invitrogen). After 6 passages (2 months), parasite strains were
labeled, mixed with DMSO and stored in liquid nitrogen.
2.3. Drug-susceptibility analysis in Leishmania promastigotes
To determine parasite susceptibility to SbIII and other anti-
leishmania drugs such as AmB, paromomycin and miltefosine,
2  105 promastigotes were incubated in 96-well plates (100 mL) at
28 C for 72 h in the presence of increasing drug concentrations
before determining cell proliferation by the MTT colorimetric assay
as described previously (Gomez-Perez et al., 2015). The 50% effec-
tive concentration (EC50) was deﬁned as the drug concentration
required for half maximal inhibition of cellular growth rate. The
EC50 for each line was calculated by nonlinear regression analysis
using SigmaPlot 2000 software for Windows (SPSS Inc., Chicago, IL,
USA). Resistance index (RI) was calculated by dividing the EC50
obtained for the resistant line by the EC50 obtained for the parental
susceptible line.
2.4. Human myelomonocytic cell line (THP-1) culture
THP-1 cells were grown at 37 C and 5% CO2 in RPMI-1640
supplemented with 10% hiFBS, 2 mM glutamate, 100 U/mL peni-
cillin and 100 mg/mL streptomycin. 3  104 cells/well, in 96-well
plates, were differentiated to macrophages with 20 ng/mL of PMA
treatment for 48 h followed by 24 h of culture in fresh medium
(Gomez-Perez et al., 2014).
2.5. Susceptibility analysis in intracellular Leishmania amastigotes
To determine the susceptibility of intracellular Leishmania
amastigotes to SbIII, SbV in the form of meglumine antimoniate
(Glucantime®), AmB, paromomycin and miltefosine, late
stationary-phase promastigotes were used to infect macrophage
differentiated-THP-1 cells at a macrophage/parasite ratio of 1:10.
Infected cell cultures were then incubated at different compound
concentrations for 72 h, as described previously (Gomez-Perez
et al., 2014). Samples were then ﬁxed for 30 min at 4 C with 2%
paraformaldehyde in PBS, followed by permeabilization with 0.1%
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ted by nuclear staining with DAPI (Invitrogen). The percentage of
infection and the mean number of amastigotes from infected
macrophages were determined in 200 macrophages/well.
2.6. Antimony accumulation and efﬂux by ICP-MS
Promastigotes (1  108 per mL) were incubated with 100 mM
SbIII for 60 min at 28 C, then centrifuged and the resultant pellet
stored at 80 C until antimony accumulation was measured as
described previously (Manzano et al., 2013). To determine anti-
mony efﬂux, the different isolates were incubated with compen-
sated SbIII concentrations (50 mM for line 576-1 and 500 mM for line
576-3) in culture medium at 28 C for 1 h to allow a similar labeling
in the Leishmania lines. The parasites were then washed with PBS,
resuspended in culture medium at 28 C and pelleted at different
times (0, 30, 60 and 120 min). The cell pellet was dissolved in
200 mL of concentrated nitric acid at room temperature for 24 h. The
sample was diluted to 3 mL with distilled water and then injected
into an inductively coupled plasma mass spectrometer (ICP-MS;
PerkinElmer) for quantitation. Antimony was measured at its m/z
ratios of 121 and 123 with rhodium as an internal standard. All
chemicals used for sample pre-treatment were of at least analytical
grade.
2.7. Nucleic acid isolation and gene expression
Genomic DNA and total RNA were extracted from the Leish-
mania isolates using the RNeasy Plus Mini Kit (Qiagen) and
DNeasy Blood and Tissue Kit (Qiagen), respectively. Isolated RNA
was transcribed into cDNA using the qScript cDNA Synthesis Kit
(Quanta Biosciences, Inc) following the manufacturer’s in-
structions. The synthetized cDNAs were diluted 1:10 and 1:50 and
speciﬁc fragments ampliﬁed with sense and antisense primers
(50-ACGATGGCGTCCAAGTACAG) and (50-GAGTATGCGAGGTGA-
CAAGTC) for aquaglyceroporin-1 (AQP1), (50-GCTGTACATGCA-
GAACGTCTC) and (50-ACGTACTCGTGCTCCACTTC) for MRPA, (50-
CTTCAACTGCATCCTCTTCG) and (50-GCAGTCCATCGAATCGCAGG)
for ornithine decarboxylase (ODC), (50-CCTCGTGTGCCGCTATC-
TAG) and (50-GCATGCGCTGCACAAGGTCA) for g-glutamylcysteine
synthetase (g-GCS), and (50-GAAGTACACGGTGGAGGCTG) and (50-
CGCTGATCACGACCTTCTTC) for GAPDH using 35 ampliﬁcation cy-
cles at an annealing temperature of 54 C. PCR products were
electrophoresed on 1% agarose gel, stained with ethidium bro-
mide, viewed under a UV illuminator and the relative intensity
against GAPDH was measured as an internal control.
The full-length coding sequence of AQP1 from L. infantum
(GeneDB L. infantum, accession code LinJ.31.0030) was isolated
from the genomic DNA of the clinical isolates by PCR using sense
and antisense primers (50-CAACAGCACGCGCACTTC) and (50-CAGT-
CAGCA CGAGCTGTG). A single-band 945 bp PCR product was ob-
tained, cloned in the pGEM®-T Vector System (Promega) and
sequenced.
2.8. Determination of intracellular levels of non-protein thiols
Intracellular non-protein thiol levels were measured by ﬂow
cytometry using CellTracker, as described previously (García-
Hernandez et al., 2012). Promastigotes (1  107 per mL) were
washed twice with PBS, incubated with 2 mM CellTracker for
15 min at 37 C, washed again with PBS and analyzed by ﬂow
cytometry using a FACScan ﬂow cytometer (Becton-Dickinson, San
Jose, CA) equipped with an argon laser operating at 488 nm.
Fluorescence emission between 515 and 545 nm was quantiﬁed
using Cell Quest software.2.9. Western blotting
For preparation of total protein lysate, L. infantum promastigotes
(3  107 per mL) were harvested, washed in PBS, lysed by the
addition of lysis buffer (2% DDM, 150 mM NaCl, 50 mM Tris-HCl pH
7.4 plus a protease inhibitor cocktail from Sigma) and incubated at
4 C for 1 h. The clariﬁed lysate was mixed with 2  Laemmli
sample buffer and resolved by SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE). The samples (25 mg protein per lane) were
resolved by 10% SDS-PAGE and transferred to PVDF membranes.
Membranes were subsequently blocked at room temperature for
1 h in 5% skimmed milk in PBS with 0.05% Tween 20 (PBS-T) and
washed three times with PBS-T. Immunodetection was performed
by incubating the blocked membranes at room temperature for 1 h
in the presence of antibodies against cytosolic tryparedoxin (cTXN),
mitochondrial tryparedoxin (mTXN), cytosolic tryparedoxin
peroxidase (cTXNPx), mitochondrial tryparedoxin peroxidase (m-
TXNPx), trypanothione synthetase (TryS) and trypanothione
reductase (TR): anti-cTXN (dilution 1:3000) (Castro et al., 2004),
anti-mTXN (1:3000) (Castro et al., 2004), anti-cTXNPx (1:3000)
(Castro et al., 2002), anti-mTXNPx (1:3000) (Castro et al., 2002),
anti-TryS (1:1000) (Sousa et al., 2014) or anti-TR (1:1000) (H. Castro
and A. Tomas, personal communication). The membranes were
washed and incubated with HRP anti-mouse IgG (1:5000) or HRP
anti-rabbit IgG (1:5000) (Promega). Immunoreactive proteins were
viewed using a chemiluminescence detection kit (Pierce ECL
Western Blotting Substrate) according to the manufacturer’s in-
structions. The results were normalized using anti-a-tubulin anti-
bodies (Sigma).
2.10. Statistical analysis
Statistical comparisons between groups were performed using
Student’s t-test. Differences were considered signiﬁcant at a level of
p < 0.005.
3. Results and discussion
3.1. Isolation of L. infantum lines from a dog with naturally acquired
leishmaniasis
In this study, we have analyzed parasites isolated from ganglion
aspirate at the time of diagnosis (MCAN/ES/2014/DP576-1, abbre-
viated as line 576-1) and 30 days after two therapeutic in-
terventions with Glucantime® (100 mg/kg/day, subcutaneously for
28 days), separated by a 30-days interval (MCAN/ES/2014/DP576-3,
abbreviated as line 576-3).
Several factors could have contributed to the absence of a
therapeutic response to Glucantime® in this dog, including factors
related to the parasite, the drug or the host. We evaluated whether
line 576-3 presents modiﬁcations in drug susceptibility that could
be associated with the development of resistance and, in positive
case, we analyzed the mechanism of resistance.
3.2. Drug susceptibility proﬁles of L. infantum isolates
The susceptibility proﬁle to SbIII of the different isolates of L.
infantum was analyzed in promastigotes and intracellular amasti-
gotes (Table 1), The EC50 values for line 576-3 were signiﬁcantly
higher than for line 576-1, in both promastigotes and intracellular
amastigotes (Table 1). These data suggest that parasites developed
resistance to SbIII after the second therapeutic intervention, pre-
senting a RI of around 6 for promastigotes and greater than 3 for
intracellular amastigotes (Table 1). Considering Glucantime® was
the drug used to treat this infected dog, we analyzed the
Table 1
Drug resistance proﬁle in L. infantum lines.
Drug L. infantum EC50 (mM) ± SD (RI)
Promastigotes Amastigotes
576-1 576-3 576-1 576-3
SbIII 17.59 ± 1.75 109.01 ± 13.63 (6.20)* 20.21 ± 2.06 >60 (>3)*
Glucantime® e e 47.80 ± 6.36 159.33 ± 24.37 (3.30)*
AmB 0.07 ± 0.02 0.04 ± 0.02 (0.57) 0.10 ± 0.01 0.06 ± 0.01 (0.60)
MLF 12.61 ± 1.50 14.72 ± 0.16 (1.16) 3.81 ± 0.30 2.03 ± 0.43 (0.53)
PMM 84.46 ± 9.08 116.05 ± 10.63 (1.37) 34.36 ± 0.76 96.13 ± 10.43 (2.79)*
Promastigotes and intracellular amastigotes of lines 576-1 and 576-3 were grown for 72 h at 28 C or 37 C in the presence of increasing drug concentrations: SbIII, Glu-
cantime®, amphotericin B (AmB), miltefosine (MLF) and paromomycin (PMM). Resistance indexes (RI) were calculated by dividing the EC50 for line 576-3 by that line 576-1.
Data are the means ± SD of three independent experiments. Signiﬁcant differences were determined using the Student’s t-test (*, p < 0.005). e, not determined.
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line 576-3, obtaining an EC50 of 159.3 mM, 3.3-fold higher than line
576-1 (Table 1). Our data clearly substantiate that relapse after the
second therapeutic intervention was due to the acquisition of drug
resistance in line 576-3.
We also studied the cross-resistance proﬁle to other anti-
leishmania drugs, including AmB, miltefosine and paromomycin
(Table 1). The results showed that intracellular amastigotes from
line 576-3 present a signiﬁcant cross-resistance to paromomycin
(RI around 2.8). However, we did not observe any cross-resistance
to AmB and miltefosine in promastigotes and intracellular amasti-
gotes. As previously described, promastigotes of L. donovani resis-
tant to antimony present a signiﬁcant cross-resistance to
paromomycin and not to AmB and miltefosine (García-Hernandez
et al., 2012); however, other studies using antimony resistant and
sensitive ﬁeld L. donovani isolates shown equal susceptibility to
paromomycin (Kulshrestha et al., 2011). These results support the
variability in the response of Leishmania to drugs. Additionally, drug
pressure could induce genomic changes in parasites that could be
responsible of the resistance to paromomycin in intracellular
amastigotes.
Furthermore, lack of correlation between the promastigote and
intracellular amastigote susceptibilities to paromomycin observed
in the present study, supports the intracellular amastigote model as
more appropriate approach for susceptibility studies, as has been
previously reported (Vermeersch et al., 2009; Kulshrestha et al.,
2011).
We then tried to elucidate the mechanism of antimony resis-
tance in line 576-3 by analyzing antimony uptake and the expres-
sion proﬁles of known genes involved in transport and thiol based
redox metabolism.
3.3. Antimony accumulation and efﬂux in L. infantum lines
A decrease in drug concentration within the parasite, either by
reducing drug uptake or by increasing efﬂux/sequestration of the
drug, represents the primary mechanism of antimonial resistance
in Leishmania (Brochu et al., 2003). To determine whether a
reduction in SbIII uptake was one of the mechanisms of resistance
developed in line 576-3, the intracellular accumulation of this
metal ion was measured by ICP-MS after incubation with 100 mM
SbIII for 1 h. SbIII accumulation was found to be signiﬁcantly lower
(90%) in the resistant line 576-3 compared to line 576-1 (Fig. 1A).
The lower SbIII accumulation in line 576-3 could explain the resis-
tance to antimonials. To determine whether the reduced level of
accumulation was due to an increase in antimony efﬂux, both L.
infantum lines were loaded under conditions that yielded similar
amounts of intracellular antimony and the portion of antimony
retained in the parasites was measured at different times. The
efﬂux of SbIII was found to be time-dependent and similar in bothLeishmania lines (Fig. 1B), thus conﬁrming that the lower SbIII
accumulation was not due to increased efﬂux activity, but rather a
decrease in drug uptake.
In Leishmania, antimony uptake is mediated by the transporter
AQP1 (Gourbal et al., 2004). Previous studies indicated AQP1 RNA
levels were down-regulated in several Leishmania promastigote
species (L. tarentolae, L. major and L. infantum) that were experi-
mentally resistant to antimonials (Marquis et al., 2005), as well as
in different antimony-resistant Leishmania donovani clinical iso-
lates (Decuypere et al., 2005; Mandal et al., 2010; Mukhopadhyay
et al., 2011).
In general, the level of AQP1 transcript correlated well with the
accumulation of SbIII and resistance levels in Leishmania parasites
(Marquis et al., 2005). AQP1 gene expression in lines 576-1 and 576-
3 was analyzed by RT-PCR to ascertain whether there was a cor-
relation between AQP1 gene expression and antimony suscepti-
bility and accumulation. The results showed that AQP1 expression
in the resistant line 576-3 was around 5-fold lower than the
expression in the susceptible line 576-1 (Fig. 1C).
Gene deletion and point mutations in AQP1 have been reported
in antimony-resistant Leishmania parasites (Monte-Neto et al.,
2015). The full-length coding sequence of the L. infantum AQP1
gene was cloned and sequenced from the 576-1 and 576-3 isolates.
Only one of ﬁve clones sequenced presented a point mutation that
lead to a premature stop codon, while the rest of the clones did not
show any point mutations or deletions that could be associated
with a reduction in AQP1 activity.
Our data therefore support the suggestion that down regulation
of AQP1 is the main resistance mechanism in L. infantum isolate
from a case of CanL with therapeutic failure.
ABC transporter MDR-related proteins (MRPA/PgpA) are known
to be involved in antimonial-resistance in Leishmania through
sequestration of the metal-thiol conjugates in an intracellular
organelle located close to the ﬂagellar pocket (Legare et al., 2001).
The role of MRPA in conferring antimony resistance by sequestra-
tion of metal-thiol conjugates has also been reported in clinical
isolates of Leishmania (Mukherjee et al., 2007).
MRPA gene expression analysis in antimony susceptible and
resistant L. infantum lines was determined by RT-PCR using speciﬁc
primers. The results showed that there were no differences in
expression levels between susceptible and resistant lines (Fig. 1D),
suggesting that MRPA is probably not responsible for the defect in
antimonial accumulation in resistant L. infantum line 576-3.
3.4. Upregulation of thiol metabolic pathway in antimony
resistance
An increase in thiol levels is considered to be one detoxiﬁcation
mechanism described in antimony-resistant L. donovani isolates
(Mandal et al., 2007; Mittal et al., 2007; Mukhopadhyay et al., 2011;
Fig. 1. Accumulation and efﬂux of SbIII in L. infantum lines. (A) Promastigotes (1  108/mL) of lines 576-1 (antimony susceptible) and 576-3 (antimony resistant) were incubated with
100 mM SbIII for 1 h. Antimony accumulation was measured by ICP-MS. The efﬂux assay (B) was performed for 1 h after incubation of lines with compensated concentrations of SbIII
to ensure similar labeling. The parasites were then washed and resuspended in PBS buffer without SbIII and pelleted at different times. The data are the means ± SD of three
independent experiments. Signiﬁcant differences were determined using the Student’s t-test (*, p < 0.001). (C) Gene expression analysis of AQP1 and (D) ABC transporter MRPA.
Total RNA was extracted from lines 576-1 and 576-3. Upper panels: gene expression of AQP1 or MRPA by RT-PCR using cDNA dilutions of 1:10 and 1:50, respectively, as indicated by
the ampliﬁed 255-bp AQP1 or 276-bp MRPA fragment. Lower panels: gene expression of GAPDH as internal loading control showing the ampliﬁed 227-bp GAPDH fragment. The RT-
PCR assay shown is representative of at least three independent experiments.
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antimony resistant line, we ﬁrst analyzed the total non-protein
thiols using CellTracker. The results, quantiﬁed in terms of rela-
tive ﬂuorescence units (RFU), demonstrate that the resistant line
576-3 showed 1.5-fold higher intracellular non-protein thiol levels
(239.17 ± 38.43 RFU) than the susceptible line 576-1
(152.57 ± 23.38 RFU), and the difference showed statistical signif-
icance (p < 0.005).
Trypanothione (T[SH]2), a conjugate of glutathione (GSH) and
spermidine, is one of the major reduced thiols in Leishmania par-
asites (Fairlamb and Cerami, 1992). Increased levels of T[SH]2 are
achieved through overexpression of g-GCS, the rate limiting
enzyme of GSH biosynthesis, and ODC, an enzyme involved in
spermidine biosynthesis (Grondin et al., 1997; Legare et al., 1997;
Haimeur et al., 1999; Guimond et al., 2003). Mechanisms of anti-
mony resistance based on T[SH]2 overproduction through over-
expression of g-GCS/ODC have previously been described in both
experimental Leishmania antimony-resistant lines and in some
clinical isolates of antimony-resistant L. donovani (Haimeur et al.,
1999; Decuypere et al., 2005; Carter et al., 2006; Mukherjee et al.,
2007; Goyeneche-Patino et al., 2008; Mandal et al., 2010; Wyllie
et al., 2010). This led us to probe the possible relationship between
intracellular thiol content and the gene expression status of g-GCS,
ODC and T[SH]2 synthetase (TryS). The results show that ODC
exhibited increased RNA levels (around 2-fold) in the antimony-
resistant line 576-3 compared to the susceptible line 576-1
(Fig. 2A), whereas g-GCS and TryS expression levels were unaf-
fected (Fig. 2). Therefore, overexpression of ODC may contribute to
increased levels of T[SH]2 in the 576-3 antimony-resistant para-
sites. The above results concur with previous reports that revealed
an increased expression of ODC in antimony-resistant isolates of
L. donovani (Mukherjee et al., 2007).In trypanosomatids, T[SH]2 is involved in the maintenance of
the intracellular reducing environment. TR is a ﬂavoenzyme that
catalyzes the NADPH-dependent reduction of trypanothione di-
sulﬁde (TS2) to T[SH]2. Previous reports have described the ampli-
ﬁcation of the TR gene in antimony-resistant L. donovani ﬁeld
isolates (Mittal et al., 2007). Using Western blot analysis we
observed a 4-fold increase in the levels of TR protein in the resistant
line versus the susceptible one (Fig. 2B). Increased levels of TR will
help to maintain increased levels of T[SH]2, which is required for
conjugationwith antimony and to overcome the inhibitory effect of
SbIII.
In Leishmania the tryparedoxin/tryparedoxin peroxidase (TXN/
TXNPx) system is crucial to defend parasites against the oxidative
stress that can be found in different compartments (Flohe et al.,
1999). Increased levels of both proteins have been detected in
antimony-resistant L. donovani ﬁeld isolates (Wyllie et al., 2010).
Leishmania have two TXNPx, one localized in the cytoplasm
(cTXNPx) and the other in the mitochondrion (mTXNPx), which
protect the cell from peroxide-induced damage (Castro et al., 2002).
Proteomic analysis of experimental antimony-resistant lines from
L. braziliensis and L. infantum showed an overexpression of cTXNPx
(Matrangolo et al., 2013). Additionally, overexpression of cTXNPx
confers resistance to antimony in L. braziliensis and L. donovani;
however, overexpression of cTXNPx in L. infantum does not seem to
be directly associated with resistance to SbIII (Lyer et al., 2008;
Andrade and Murta, 2014). Therefore, we studied whether TXN/
TXNPx proteins were upregulated in the antimony-resistant line
576-3. The results showed an overexpression of mTXN (by around
12-fold) and mTXNPx (around 4-fold), while no differences were
observed in the expression of cTXN and cTXNPx (Fig. 2B). The
overexpression of the mitochondrial pathway could induce an in-
crease in T[SH]2 levels which forms a complex with SbIII, thus
Fig. 2. Expression of genes related to thiol metabolism. (A) Gene expression analysis of ODC and g-GCS in L. infantum lines. Total RNA was extracted from lines 576-1 (antimony
susceptible) and 576-3 (antimony resistant). Upper panels: gene expression by RT-PCR as indicated by the ampliﬁed 253-bp ODC and 200-bp g-GCS fragments. Lower panels: gene
expression of GAPDH as internal loading control showing the ampliﬁed 227-bp GAPDH fragment. RT-PCR assay shown is representative of at least three independent experiments.
The positions of molecular markers (bp) are indicated on the left. (B) Western blot analysis of thiols metabolizing enzymes TR, TryS, m-TXN, c-TXN, m-TXNPx, c-TXNPx in L. infantum
lines. Anti-a-tubulin antibodies were used for loading control. Western blots shown are representative of at least three independent experiments. The positions of molecular
markers (kDa) are indicated on the left.
V. Gomez Perez et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 133e139138inactivating the toxic effects of antimony and enhancing the para-
site’s antioxidant defense.4. Conclusions
The present study has characterized the mechanisms of antimony
resistance for theﬁrst time in a clinical isolate of L. infantum from a dog
with naturally acquired CanL.We conﬁrmed that L. infantum line 576-3
confers resistance against SbIII by signiﬁcantly decreasing expression
of the AQP1 transporter which leads to a reduction in intracellular
accumulation of SbIII. Other factors including an increase in thiols
levels and overexpression of enzymes involved in thiol metabolism
could also contribute to the SbIII detoxiﬁcation mechanism.
A major contribution of this study in a canine L. infantum isolate
is to ﬁnd an antimony-resistant mechanism similar to that previ-
ously described in other human clinical isolates. Therefore, more
studies are required in L. infantum isolates from dogs that relapse
after treatment to better understand the therapeutic failure in
CanL. The use of naturally infected dogs and a controlled thera-
peutic intervention represent an excellent experimental strategy to
study therapeutic failure/resistance and search for more effective
therapeutic strategies following relapse, to avoid the spread of
drug-resistant lines in endemic areas in attempts to control the
disease. However, the use of naturally infected dogs has limitations
mainly due to the economic costs and the requirements and con-
trols to prevent new reinfections and follow-up analyses for drug
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